28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Across New England stakeholders are promoting healthy aging by building age-friendly communities (healthyagingdatareports.org). 1 key finding →
Participants: 367 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Individuals aged 70 and above experiencing memory loss in Cochran and Parmer Counties had a statistically significant association with cognitive impairment (p < 0.001). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Social isolation (SI) and loneliness (perceived social isolation) are considered as risk factors for developing dementia, including Alzheimer's disease (AD), in the elderly population. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Researchers are focusing on modifiable risk factors for dementia, including sleep disturbances such as insomnia and sleep-disordered breathing (SDB), which are known to increase the risk of dementia, including Alzheimer’s disease (AD) and vascular dementia (VD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Acute ischemic stroke often results in a multitude of neuropsychiatric complications, including depression, dementia, delirium, and fatigue. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Health concerns seem to influence consumers’ decisions for purchasing local foods. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Benefits Beyond Auditory Rehabilitation Research conducted by Frank Lin and colleagues found that individuals with untreated mild, moderate, and severe hearing loss had, respectively, a twofold, threefold, and fivefold increased risk of dementia compared with individuals with normal hearing. 4 Research suggests that early auditory rehabilitation is important for people of all ages, including older adults, as it can provide benefits and improvements beyond hearing ability such as cognitive function and mitigation of depression. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Parameters such as clinical status, GCA scale, MTA scale, Fazekas scale, strategic infarction, Koedam score, stroke, hypertension, diabetes mellitus, dyslipidemia, and cardiovascular disease do not have significant correlations with MoCA-INA scores. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This review analyzes current data on the epidemiology, pathogenesis, clinical features, and approaches to the treatment of cognitive impairments in diabetes mellitus (DM). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive training appears effective in improving cognitive functions and delaying cognitive decline in people at risk of Alzheimer's disease but requires more standardized research for conclusive evidence. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This paper examined the prevalence of and risk factors associated with unmet needs for activities of daily living (ADL) for older adults dying with dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease is a neurodegenerative disorder whose etiology continues to be discussed, to the point that there are different hypotheses that seek to clarify it, in addition to the fact that, given its multifactorial nature, there are different risk factors associated with its development. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Various medicinal agents aimed at improving Alzheimer disease (AD) include cholinesterase inhibitors, memantine, aducanumab, and antioxidants. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These findings highlight the variability in the cumulative patterning of racial discrimination and stress among midlife and older Black adults, providing insights into how these factors impact health outcomes in middle to late life. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The fall caused a sprained wrist and significant bruising to her hip, and although her scrapes and bruises healed, she was left with an overwhelming fear of falling again. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The disease-related mortality from chronic non-communicable diseases is an emerging issue of global health in middle to high income countries. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Small area estimates (SAEs) are increasingly used in public health to assess disease and health behavior prevalence rates at more local levels of geography, better informing public health decision-making and interventions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The results of this study confirm that some sociodemographic groups are more likely to choose priorities that reflect contextual constraints in their lives than others. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We know that lifestyle changes, such as to diet and exercise regimens, can have an impact on the risk of developing dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We investigated whether vascular and lifestyle factors are associated with AD plasma and imaging biomarkers in midlife. 4 key findings →
Participants: 1,406 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We estimated associations of educational attainment and Alzheimer disease genetic risk with treatment initiation and incident dementia and compared GLP-1 receptor agonist initiators with initiators of non-sodium-glucose cotransporter 2 inhibitor second-line therapies, with a separate sodium-glucose cotransporter 2 inhibitor compa 4 key findings →
Design: cohort study Participants: 14,364 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
It is estimated that for people aged 65 years and older, the risk of developing Alzheimer’s disease was nearly double for women compared with men (Weinstein et al., 2012). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Body mass index (BMI), type 2 diabetes (T2D) and related cardiometabolic features associate with Alzheimers disease (AD) risk, yet shared mechanisms remain poorly understood. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundThe brain age gap (BAG), the difference between neuroimaging-predicted and chronological age, captures inter-individual variation in brain aging. 2 key findings →
Design: longitudinal study Participants: 202 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
AbstractO_ST_ABSBackgroundC_ST_ABSGlucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly used for type 2 diabetes. 5 key findings →
Participants: 6,328 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →